Inotiv (NASDAQ:NOTV – Get Free Report) and Ernexa Therapeutics (NASDAQ:ERNA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.
Analyst Recommendations
This is a summary of recent recommendations for Inotiv and Ernexa Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inotiv | 1 | 0 | 1 | 0 | 2.00 |
| Ernexa Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Inotiv presently has a consensus price target of $3.00, indicating a potential upside of 393.91%. Given Inotiv’s stronger consensus rating and higher probable upside, equities analysts plainly believe Inotiv is more favorable than Ernexa Therapeutics.
Volatility and Risk
Earnings and Valuation
This table compares Inotiv and Ernexa Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inotiv | $513.02 million | 0.04 | -$68.62 million | ($2.22) | -0.27 |
| Ernexa Therapeutics | $580,000.00 | 17.73 | -$44.54 million | ($3.01) | -0.44 |
Ernexa Therapeutics has lower revenue, but higher earnings than Inotiv. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than Inotiv, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
18.2% of Inotiv shares are held by institutional investors. Comparatively, 70.6% of Ernexa Therapeutics shares are held by institutional investors. 7.8% of Inotiv shares are held by insiders. Comparatively, 4.5% of Ernexa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Inotiv and Ernexa Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inotiv | -13.38% | -17.15% | -3.39% |
| Ernexa Therapeutics | N/A | -1,950.55% | -304.60% |
Summary
Inotiv beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.
About Inotiv
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
About Ernexa Therapeutics
Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for Inotiv Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inotiv and related companies with MarketBeat.com's FREE daily email newsletter.
